Some molecular biological markers are important for determining molecular subtypes, individualized treatment, and predicting prognosis, such as MGMT [7], EGFR [8], IDH [9], 1p19q [10], ATRX [11], MGMT promoter methylation levels, 1p/19q-codeleted and IDH1 mutations can predict the prognosis of GBM, oligodendroglioma (OD) and low grade glioma [12]. The gene discussed is IDH2; the disease is glioblastoma.